A number of other analysts also recently commented on the stock. Bank of America boosted their target price on shares of Chemed from $470.00 to $500.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Oppenheimer boosted their target price on shares of Chemed from $400.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Finally, Royal Bank of Canada boosted their target price on shares of Chemed to $405.00 and gave the stock a “sector perform” rating in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $411.25.
Shares of NYSE CHE traded down $1.91 during midday trading on Wednesday, reaching $412.47. The company’s stock had a trading volume of 57,339 shares, compared to its average volume of 124,742. The company has a current ratio of 0.81, a quick ratio of 0.78 and a debt-to-equity ratio of 0.25. The company has a 50 day moving average price of $425.22 and a 200 day moving average price of $368.67. Chemed has a one year low of $260.03 and a one year high of $441.79. The company has a market cap of $6.57 billion, a price-to-earnings ratio of 34.57, a price-to-earnings-growth ratio of 2.80 and a beta of 1.11.
In related news, Director Walter L. Krebs sold 2,910 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $430.41, for a total value of $1,252,493.10. Following the sale, the director now directly owns 9,318 shares in the company, valued at approximately $4,010,560.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin J. Mcnamara sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $432.73, for a total transaction of $2,163,650.00. Following the completion of the sale, the insider now owns 134,712 shares in the company, valued at $58,293,923.76. The disclosure for this sale can be found here. Insiders sold a total of 46,812 shares of company stock worth $20,005,507 over the last quarter. Insiders own 3.96% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC raised its holdings in shares of Chemed by 117.9% during the second quarter. Advisory Services Network LLC now owns 85 shares of the company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Neuburgh Advisers LLC raised its holdings in shares of Chemed by 9.9% during the first quarter. Neuburgh Advisers LLC now owns 3,400 shares of the company’s stock valued at $1,088,000 after acquiring an additional 306 shares during the period. Creative Planning raised its holdings in shares of Chemed by 25.9% during the second quarter. Creative Planning now owns 822 shares of the company’s stock valued at $297,000 after acquiring an additional 169 shares during the period. Great Lakes Advisors LLC raised its holdings in shares of Chemed by 4.2% during the second quarter. Great Lakes Advisors LLC now owns 29,380 shares of the company’s stock valued at $10,602,000 after acquiring an additional 1,190 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Chemed during the second quarter valued at approximately $7,505,000. Institutional investors and hedge funds own 87.12% of the company’s stock.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Further Reading: Can systematic risk be avoided?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.